Penumbra, Inc. (PEN) Shares Bought by Russell Investments Group Ltd.
Russell Investments Group Ltd. boosted its stake in Penumbra, Inc. (NYSE:PEN) by 208.0% during the second quarter, Holdings Channel reports. The fund owned 160,033 shares of the company’s stock after buying an additional 108,080 shares during the period. Russell Investments Group Ltd.’s holdings in Penumbra were worth $14,043,000 as of its most recent filing with the SEC.
A number of other institutional investors have also recently bought and sold shares of the company. Ameritas Investment Partners Inc. purchased a new position in Penumbra during the first quarter valued at $194,000. Simplex Trading LLC boosted its position in Penumbra by 11.5% in the first quarter. Simplex Trading LLC now owns 2,565 shares of the company’s stock valued at $214,000 after buying an additional 265 shares during the last quarter. FNY Partners Fund LP purchased a new position in Penumbra during the first quarter valued at $223,000. Amalgamated Bank purchased a new position in Penumbra during the first quarter valued at $274,000. Finally, Suntrust Banks Inc. boosted its position in Penumbra by 1.8% in the first quarter. Suntrust Banks Inc. now owns 3,922 shares of the company’s stock valued at $327,000 after buying an additional 71 shares during the last quarter. Hedge funds and other institutional investors own 69.01% of the company’s stock.
Penumbra, Inc. (NYSE PEN) traded down 2.84% during trading on Friday, hitting $85.45. 214,097 shares of the stock traded hands. The company’s 50 day moving average is $85.47 and its 200 day moving average is $82.17. The company has a market capitalization of $2.89 billion, a P/E ratio of 577.36 and a beta of 0.10. Penumbra, Inc. has a one year low of $56.05 and a one year high of $91.00.
Penumbra (NYSE:PEN) last posted its earnings results on Tuesday, August 8th. The company reported ($0.05) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.05). The company had revenue of $80.60 million for the quarter, compared to analyst estimates of $77.16 million. Penumbra had a negative net margin of 2.78% and a negative return on equity of 2.58%. The business’s revenue for the quarter was up 23.8% compared to the same quarter last year. During the same period last year, the business posted $0.01 earnings per share. On average, equities analysts forecast that Penumbra, Inc. will post ($0.21) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Penumbra, Inc. (PEN) Shares Bought by Russell Investments Group Ltd.” was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/08/11/penumbra-inc-pen-shares-bought-by-russell-investments-group-ltd.html.
PEN has been the topic of several research analyst reports. BidaskClub upgraded shares of Penumbra from a “hold” rating to a “buy” rating in a research report on Thursday, June 22nd. BMO Capital Markets reiterated a “buy” rating and set a $96.00 price objective on shares of Penumbra in a research report on Friday, June 16th. Canaccord Genuity reiterated a “buy” rating and set a $94.00 price objective on shares of Penumbra in a research report on Tuesday, June 13th. Finally, Zacks Investment Research cut shares of Penumbra from a “hold” rating to a “sell” rating in a research report on Thursday, May 11th.
In other Penumbra news, Director Thomas Wilder sold 345 shares of the stock in a transaction on Tuesday, July 18th. The shares were sold at an average price of $86.10, for a total value of $29,704.50. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Daniel Donen Davis sold 32,000 shares of the stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $79.42, for a total transaction of $2,541,440.00. The disclosure for this sale can be found here. Company insiders own 22.00% of the company’s stock.
Penumbra Company Profile
Penumbra, Inc is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.
Want to see what other hedge funds are holding PEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Penumbra, Inc. (NYSE:PEN).
Receive News & Ratings for Penumbra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.